LivaNova reports Q4 adjusted EPS 81c, consensus 80c

Reports Q4 revenue $321.8M, consensus $324.11M. “In 2024, LivaNova (LIVN) delivered strong revenue growth, expanded operating margin, and significantly improved cash generation,” said Vladimir Makatsaria, CEO of LivaNova. “We are pleased with these results and the clinical milestones achieved in both the obstructive sleep apnea and difficult-to-treat depression programs. We look forward to building on this momentum in 2025 with a continued focus on talent, innovation, growth, and operational excellence.”